The group's principal activity is to develop and design drug delivery technology for pharmaceuticals, vaccines and over-the-counter drugs. The proposed drug delivery technology encapsulates or wraps the selected drug in a jellyroll-like structure termed as a cochleate cylinder. These drugs may be marketed under the brand name bioral. The group operates in the United States. On 24-Aug-2004, the group acquired arius pharmaceuticals inc.
